2020 TOPICS:
SC1, EDCTP, AAL & IMI

PATRÍCIA CALADO

Excellent Science
~ 24 400 M€

European Research Council
Frontier Research by the best individual teams

Future and Emerging Technologies
Collaborative research to open new fields of innovation

Marie Skłodowska-Curie Actions
Opportunities for training and career development

Research Infrastructures
(including e-infrastructure)
Ensuring access to world class facilities

Bottom up

Industrial Leadership
~ 17 800 M€

Leadership in enabling and industrial technologies
Space, ICT, NMBP *(nanotechnologies, advanced materials, biotechnology, manufacturing)*

Access to Risk finance
Leveraging private finance and venture capital for research

Innovation in SMEs
Fostering all forms of innovation in all types of SMEs

Top down

Societal Challenges
~ 29 700 M€

1. **Health,** demographic change and wellbeing
2. Food security, sustainable agriculture, marine and maritime research & the **bioeconomy**
3. Secure, clean and efficient **energy**
4. Smart, green and integrated **transport**
5. Clima**te action**, environment, resource efficiency and raw materials
6. Inclusive, innovative and reflective **societies**
7. **Security** society

Top down

European Institute of Innovation and Technology (EIT) (~2700 M€)

Spreading Excellence and Widening Participation (~1900 M€)

Science with and for Society (~1600 M€)

Joint Research Centre (JRC)

Health, Demographic Change &Wellbeing 7.257 M€

IMI2 1.638 M€

AAL 175 M€

EDCTP 683 M€

HEALTH, DEMOGRAPHIC CHANGE AND WELL-BEING

Health collaborative research

**7 priorities for 2018-2020**

Personalised medicine

Decoding the role of the environment for health and well-being

Infectious diseases and improving global health

Innovative health and care industry

Innovative health, and care systems - Integration of care

Digital transformation in Health and Care

Trusted Big Data solutions and Cybersecurity for Health and Care

650 M€

STRATEGIC PRIORITIES, OBJECTIVES, POLICY DRIVERS

RELEVANT BACKGROUND

2030 Agenda for Sustainable Development and its Sustainable Development Goals

COP211

Ostrava declaration on environment and health

Digital Single Market

European One Health Action Plan against Antimicrobial Resistance

Cross-border healthcare directive (and its support to the European Reference Networks)

Commission Communication on upgrading the single market

Council Conclusions on Personalised Medicine and on Pharmaceuticals

SC1 WP 2020

3 CALLS

36 TOPICS

650 M€

Deadlines

- 24.09.2019 (4 topics two stage)

- 13.11.2019 (3 topics single stage)

- 07.04.2020 (21 topics single stage)

- 22.04.2020 (8 topics single stage)

RIA; 19
IA; 1
CSA; 11
PCP; 2
PPI; 1
ERA-NET; 3

RIA   IA   CSA   PCP   PPI   ERA-NET

WP 2020: 3 CALLS FOR PROPOSALS

BETTER HEALTH AND CARE, ECONOMIC GROWTH AND SUSTAINABLE HEALTH SYSTEMS — 22

Personalised medicine — 6

Innovative health and care industry — 4

Infectious diseases and improving global health — 7

Innovative health and care systems – Integration of care — 3

Decoding the role of the environment, including climate change, for health and well-being — 2

DIGITAL TRANSFORMATION IN HEALTH AND CARE — 12

TRUSTED DIGITAL SOLUTIONS AND CYBERSECURITRY IN HEALTH AND CARE — 3

Priority 1.1 Personalised medicine

Strategic goals :

❑ Delivering personalised health and care solutions to benefit citizens;

❑ Generate and translate knowledge on disease aetiology and technological innovation into personalised health and care solutions;

❑ Areas of application include chronic, rare and communicable diseases;

❑ Any type of population, including children, the ageing population and high-risk groups;

❑ Relevant links with the European Reference Networks will be sought;

❑ Develop an understanding of the economic impact and the potential of personalised medicine to transform health systems.

Priority 1.2 Innovative health and care industry

Strategic goals :

❑ Turning innovative knowledge and technologies into practical applications benefiting citizens, healthcare systems and businesses;

❑ Areas of research include innovative disgnostics and therapeutics, including advanced therapies;

❑ SMEs are na important component and target of this priority;

❑ Actions must demonstrate clear exploitation potential and socioeconomic benefits for patients and sustainable health systems;

❑ Complementarity with activities under the SME Instrument, the Fast Track to Innovation and the Innovative Medicines Initiative.

Priority 1.3 Infectious diseases and improving global health

Strategic goals :

❑ Tackle infectious diseases and the health of vulnerable groups;

❑ "One Health" and more personalised approach to target the improvement of risk assessment and surveillance tools, the development of innovative medical countermeasures addressing AMR, emerging and re-emerging infectious diseases and poverty-related and neglected diseases, low-vaccine uptake;

❑ Maternal and newborn health, global collaboration on NCD and brain research;

❑ Up-scaling interventions in specific diseases to populations in LMIC and in vulnerable populations of HIC;

❑ Connection between global health and extensive migration waves;

❑ Links to the EDCTP, the EU and WHO Global AMR action plans, the European One Health Action Plan against AMR, etc.

Priority 1.4 Innovative health and care systems - Integration of care

Strategic goals :

❑ Developing effective, accessible and sustainable health interventions and integrated care systems;

❑ Particularly relevant in the context of personalised medicine, management of chronic diseases and health promotion;

❑ Development of health technology assessment methods and evaluation of community- and population-based intervention strategies;

❑ Management of elderly multimorbid patients;

❑ New financing and business models, requiring contributions from SSH;

❑ Intergation of the healthcare dimension by better coordinating primary and comunity care with the specific needs of the patient.

Priority 1.5 Decoding the role of the environment, including climate change, for health and well-being

<u>**Strategic goals**</u> :

❑ Access the impact of environment on health and well-being, and the related socio-economic impacts;

❑ Development of new testing and screening methods to identify endocrine disrupting chemicals;

❑ Development of the 'human exposome', allowing the assessment of the totality of the life-long environmental influences that individuals are exposed to and their health impacts;

❑ Understanding the impact of micro- and nano-plastics on human health;

❑ Development of a European environment and health research agenda for the future;

❑ Innovative actions for improving urban health and wellbeing;

❑ Contribution to the Ostrava Declaration on Environment and Health and the EU chemical and other sectoral policies;

❑ Build on existing results from projects funded under previous EU research framework programmes and create links to the European Human Biomonitoring.

Strategic goals :

❑ Supporting the management of health and wellbeing while empowering the participation of citizens and facilitating the transformation of health and care services to more digitised, person-centred and community-based care models;

❑ Enabling better access to healthcare and the sustainability of health and care systems;

❑ Secure and interoperable data as an enabler together with state of the art technologies such as Artificial Intelligence and Big Data analytics are essential building blocks for the digital transformation of health and care;

❑ Relevant to the Commission priorities 'A new boost for jobs, growth and investment' and 'A connected Digital Single Market' , as well as to the European Cloud Initiative and the European Free Flow of Data Initiative;

❑ Maximising the potential of the digital economy in the health and care sectors aiming at sustainable development to the benefit of society, environment and citizens.

CALL TRUSTED DIGITAL SOLUTIONS AND CYBERSECURITY IN HEALTH AND CARE

Strategic goals :

❑ Multidisciplinary technologies and solutions in health and care with a focus on Artificial Intelligence, High Performance Computing and cybersecurity to assure data privacy, security and protection of health and care infrastructures;

❑ Addresses the need for secure and user-driven ICT-based solutions in early risk detection and interventions with big data approaches that enable aggregation of a variety of new and existing data sources such as medical records, registries, social platforms and other environmental, physiological and behavioural data, including data from large scale pilots on smart living environments;

❑ Contribute to the Focus Areas on 'Digitising and transforming European industry and services' and 'Boosting the effectiveness of the Security Union'.

HEALTH INFO DAY AND BROKERAGE EVENT

3 July

Home > Research and Innovation > Events

Save the date! Open Info Day, Horizon 2020 - 'Health, demographic change and wellbeing'

Brussels (Charlemagne building), Belgium

4 July

4 July 2019
Brussels, Belgium

Horizon 2020 Health Partnering Day 2019

#H2020PartnerHealth

Home   How it works?   Timetable   Flash presentations   Venue   Contact

Get involved in the next H2020 Health proposals!

Register now
Open until 31 May 2019

The launch of the 2020 call is planned for June 2019; this will be the last call of Horizon 2020 before the new Framework Programme starts in 2021.

LOCATION
Crowne Plaza Brussels - Le Palace

The European action Health NCP Net 2.0, in partnership with *Enterprise Europe Network*, are organizing the next Horizon 2020 Partnering Day on the 2020 Health call for proposals.

This international partnering event will help you to build your consortium for the upcoming 2020 calls of the 2018-2020 Health work programme, which will be open until April 2020.

ORGANISED BY

HNN 2.0
HEALTH-NCP-NET

Don't miss this opportunity!

This event will target a wide spectrum of companies, universities and researchers from Europe and beyond interested in sharing new project ideas.

enterprise
europe
network

One day before, on the 3rd of July 2019, the European Commission is organizing an **Open Info Day** dedicated to "Health, Demographic Change & Wellbeing (SC1)" challenge in Horizon 2020 and focusing on the 2020 call.

Do not miss an opportunity to attend both of these events and establish valuable contacts with other experts as well as European Commission representatives!

HEALTH RELATED PROGRAMMES

(CO-FUNDED BY SC1)

EDCTP funds clinical research to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.

Contact: ricardo.pereira@fct.pt

AAL funds projects that work towards creating market-ready products and services for older people. Each project consists of SMEs, research bodies and end-user organisations. Time-to-market maximum 2-3 years after the end of the project.

Contact: pedro.ruivo@fct.pt

IMI is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalised medicines for the health and wellbeing of all, especially in areas of unmet medical need.

Contact: patricia.calado@ani.pt

The EIP on AHA aims to promote healthy and active ageing. Its overarching target is to increase the average healthy lifespan of EU citizens by 2 years by the year 2020. It pursues a Triple Win for Europe:

• Improving the health and quality of life of Europeans with a focus on older people;

• Supporting the long-term sustainability and efficiency of health and social care systems;

• Enhancing the competitiveness of EU industry through business and expansion in new markets.

EUROPEAN & DEVELOPING COUNTRIES CLINICAL TRIALS PARTNERSHIP (EDCTP)

➢ Created in 2003 as a European **response to the global health crisis** caused by the three main poverty-related infectious diseases, **HIV/AIDS, tuberculosis and malaria**;

➢ Brings together **EU Member States** plus **Norway**, **Sub-Saharan African countries**, **pharmaceutical companies**, small and medium enterprises (**SMEs**), product development partners (**PDPs**) and international foundations.

➢ Main goal:

o Acceleration of the development of **new or improved tools** (drugs, microbicides, diagnostics and vaccines) against **poverty-related diseases**;

➢ Other goals:

o To coordinate the European national programmes to effectively work in synergy and in mutual partnership with other stakeholders;

o To develop and strengthen the capacities in sub-Saharan Africa to ensure that the relevant clinical trials are conducted using best practice;

o To develop closer partnerships with third parties to more effectively deliver the objectives of the programme.

EDCTP

EDCTP 2019 CALLS FOR PROPOSALS

Research and Innovation Actions (RIA)

RIA	RIA	RIA	RIA	RIA
Strategic actions supporting large-scale clinical trials	New drugs and vaccines for priority pathogens in antimicrobial resistance	Paediatric drug formulations for poverty-related diseases	Strategic actions on product-related implementation research	Vaccines against Lassa virus – joint call with CEPI

Coordination and Support Actions (CSA)

CSA
Ethics and regulatory capacities

Training and Mobility Actions (TMA)

TMA	TMA	TMA	TMA
Career Development Fellowships	EDCTP-AREF Preparatory Fellowships	EDCTP-TDR Clinical Research and Product Development Fellowships	Senior Fellowships Plus

Opening date: 3 June 2019 **Deadline:** 7 Nov 2019	**Opening date:** 3 June 2019 **Deadline:** 7 Nov 2019	**Opening date:** 10 June 2019 **Deadline:** 10 Oct 2019	**Opening date:** 10 June 2019 **Deadline:** 21 Dec 2019	**Opening date:** 2 Nov 2019 **Deadline:** 7 April 2020	**Opening date:** 2 Aug 2019 **Deadline:** 22 Nov 2019	**Opening date:** 6 Aug 2019 **Deadline:** 27 Nov 2019	**Opening date:** 6 Aug 2019 **Deadline:** 27 Nov 2019	**Opening date:** 1 Oct 2019 **Deadline:** 28 Feb 2020	**Opening date:** 2 Nov 2019 **Deadline:** 1 Feb 2020

Full proposal evaluation results available on or before:

30 March 2020	30 March 2020	24 July 2020	10 June 2020	30 June 2020	16 April 2020	19 April 2020	19 April 2020	28 July 2020	1 June 2020

Grant preparations to follow: 1-3 months

Grant agreement signed by:

June 2020	June 2020	October 2020	September 2020	September 2020	July 2020	July 2020	July 2020	October 2020	October 2020

Project duration:

36-60 months	36-60 months	36-60 months	24-48 months	36-60 months	24-36 months	36 months	12 months	Placements 15 months + 6 months return phase	60 months

One-stage application procedure →

Two-stage application procedure →

E D C T P

ACTIVE ASSISTED LIVING PROGRAMME (AAL)

➢ O Programa Conjunto "Active and Assisted Living" (AAL) teve início em 2007 e traduz-se no financiamento integrado dos **estados parceiros da Associação AAL**, com o apoio financeiro da **União Europeia**;

➢ O objetivo do Programa AAL é o de **gerar soluções inovadoras baseadas em TIC**.

➢ Estas soluções visam:

o Melhorar a **qualidade de vida dos idosos**;

o Melhorar a **sustentabilidade** a longo prazo dos **sistemas de cuidados de saúde** e de **cuidados continuados**;

o Potenciar o usufruto das **oportunidades** que emergem com o **envelhecimento demográfico**, na **Europa** e a nível **internacional**.

AS SOLUÇÕES FINANCIADAS PELO PROGRAMA AAL SÃO:

➢ 1) Desenvolvidas através do **trabalho colaborativo** entre entidades parceiras de natureza diversa (instituições de ensino superior, instituições ligadas a I&D, empresas e utilizadores finais) e **transnacional** (parceiros de pelo menos três países membros da Associação AAL);

➢ 2) Centradas nas **necessidades dos utilizadores finais** (idosos, cuidadores formais e informais, familiares e vizinhança, organizações de assistência; instituições públicas ou privadas, serviços públicos, municípios, sistemas de segurança social, empresas de seguros, empresas de habitação, entre outros);

➢ 3) Custos compartilhados entre **público e privado**; foco em projetos que sejam sustentáveis após o período de financiamento (**time-to-market de 2-3 anos** no máx.)

Call 2019 encerrada a 24 maio, nova call em 2020

INNOVATIVE MEDICINES INITIATIVE (IMI2)

➢ **PPP** between the **European Union** and the European Federation of Pharmaceutical Industries and Associations (**EFPIA**).

➢ **€3.3 billion budget** for the period **2014-2020** with the following goals:

o **improve** the current **drug development** process by providing support for the **development of tools**, **standards** and **approaches** to assess **efficacy**, **safety** and **quality** of regulated health products;

o develop **diagnostic and treatment biomarkers** clearly linked to clinical relevance and approved by regulators;

o reduce the time to reach clinical **PoC in cancer**, **immunological**, **respiratory**, **neurological** and **neurodegenerative** diseases;

o increase the **success rate in clinical trials** of **priority medicines** identified by the WHO;

o develop **new therapies** for diseases for which there is a **high unmet need** (Alzheimer's, AMR);

o reduce the **failure rate of vaccine candidates** in phase III clinical trials through **new biomarkers** for initial efficacy and safety checks.

IMI2 CALL 18 TOPICS

- Central repository of digital pathology slides to support the development of artificial intelligence tools

- Health Outcomes Observatories – empower patients with tools to measure their outcomes in a standardised manner creating transparency of health outcomes

- Improving patient access, understanding and adherence to healthcare information: an integrated digital health information project

- Establishing international standards in the analysis of patient reported outcomes and health-related quality of life data in cancer clinical trials

- Accelerating research & development for advanced therapy medicinal products

- Supporting the development of chimeric antigen receptor T cells

Currently planned for 26/06/2019 (indicative)

Webinars on Call 18 from 14 to 26 June

NATIONAL PARTICIPATION IN HORIZON 2020

PATRÍCIA CALADO

PORTUGAL IS A NET BENEFICIARY OF H2020

FP6	FP7	H2020
1,33%	1,31%	1,30%
1,01%	1,15%	1,65%

PT has been a net beneficiary since 2012, during the last 2 years of FP7.

PORTUGUESE PARTICIPATION

PERIN – Portugal in Europe Research and Innovation Network | duplicar a presença Portuguesa nos Programas Europeus

PT RESULTS 2014-2018

Proposals: 11334

Projects: 1618

Coordinated projects: 473

Participations: 2348

PT Funding :

% PT: 1,65

728,91 M€

|	
Higher Education	**198,1 M€**
Research Centers	**273,1 M€**
Industry	**193,8 M€**
	(SMEs : 117,9 M€)

PT RESULTS BY THEMATIC AREA

Evaluated calls 2014 – 2018

Return Rate

1,65%

Excellence | Industrial Leadership | Societal Challenges | Horizontal | JTI

ERC 1,21% · FET 1,22% · Marie Curie 1,77% · Infraestruturas 1,01% · NMP+B 2,03% · ICT 1,75% · Espaço 2,16% · Cap. Risco 0,90% · Apoio a PME 1,25% · Fast Track 1,73% · Instrumento PME 1,28% · Saúde 1,23% · Bio Economia 2,34% · Energia 2,19% · Transportes 1,08% · Ação Climática 2,27% · Sociedades 1,78% · Segurança 2,96% · Widening 10,39% · SWAFS 2,41% · Fissão 0,39% · Fusão 2,34% · BBI 0,81% · Cleansky 0,98% · ECSEL 0,50% · IMI 0,48% · FCH-JU 0,08% · SESAR 0,45% · Shift2Rail 1,27%

PT PROJECTION FOR 2020

PT PROJECTION FOR 2027

Millions

2 000,00 €

1 800,00 €

1 600,00 €

1 400,00 €

1 200,00 €

1 000,00 €

800,00 €

600,00 €

400,00 €

200,00 €

0,00 €

3,4 x

1,8 x

2,0 x

FP6   FP7   H2020   Horizon Europe

■ Secured   ▨ Projected 2018   ■ Projected 2019-2020

Horizon Europe (HE) +

Digital Europe Programme +

Space Programme +

Defense Programme

PERIN – Portugal in Europe Research and Innovation Network | duplicar a presença Portuguesa nos Programas Europeus

Thank you!

Patrícia Calado

patricia.calado@ani.pt